Smith & Nephew plc (SNN)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- Symbol
- SNN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $12.07B
- 52 week range
- 26.69 - 37.51
Valuation
- Share price
- $26.82 (close of 2026-09-23)
- P/E (TTM)
- 19.07x
- Price to book
- 2.28x
- Price to free cash flow
- 14.17x
- Enterprise value
- $14.84B
- Book value per share
- $12.05
Price performance
| Period | Change |
|---|
| 1 day | -3.14% |
| 5 days | -4.25% |
| 1 month | -8.34% |
| 3 months | -9.42% |
| 6 months | -16.03% |
| Year to date | -18.26% |
| 1 year | -25.71% |
| 3 years | +5.76% |
| 5 years | -27.32% |
| 10 years | -19.58% |
| All time | +297.33% |
Profitability and growth
- Return on equity
- 11.82%
- Return on invested capital
- 7.94%
- Return on assets
- 5.98%
- Return on capital employed
- 8.96%
- Gross margin
- 68.01%
- Net margin
- 10.14%
- EBITDA margin
- 12.88%
- Revenue growth
- 6.09%
- Net income growth
- 51.70%
- Free cash flow growth
- 40.59%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.06%
- Current ratio
- 2.57x
- Net debt to EBITDA
- 1.81x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $6.16B
- Cost of revenue
- $1.97B
- Gross profit
- $4.19B
- EBITDA
- $794.00M
- Net income
- $625.00M
- Earnings per share
- $1.44
- Research and development
- $296.00M
- Shares outstanding
- 433.50M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $6.16B | $4.19B | $625.00M | $1.44 |
| 2024-12-31 | $5.81B | $4.05B | $412.00M | $0.94 |
| 2023-12-31 | $5.55B | $3.82B | $263.00M | $0.60 |
| 2022-12-31 | $5.21B | $3.67B | $223.00M | $0.51 |
| 2021-12-31 | $5.21B | $3.67B | $524.00M | $1.20 |
| 2020-12-31 | $4.56B | $3.16B | $448.00M | $1.03 |
| 2019-12-31 | $5.14B | $3.80B | $600.00M | $1.37 |
| 2018-12-31 | $4.90B | $3.61B | $663.00M | $152.00 |
| 2017-12-31 | $4.76B | $3.52B | $767.00M | $1.76 |
| 2016-12-31 | $4.67B | $3.40B | $784.00M | $1.76 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 68.01% | 10.14% | 11.82% | 7.94% |
| 2024-12-31 | 69.64% | 7.09% | 7.83% | 7.17% |
| 2023-12-31 | 68.82% | 4.74% | 5.04% | 4.98% |
| 2022-12-31 | 70.47% | 4.28% | 4.24% | 5.63% |
| 2021-12-31 | 70.40% | 10.05% | 9.41% | 10.80% |
| 2020-12-31 | 69.39% | 9.82% | 8.49% | 7.35% |
| 2019-12-31 | 73.96% | 11.68% | 11.67% | 13.23% |
| 2018-12-31 | 73.53% | 13.52% | 13.60% | 12.40% |
| 2017-12-31 | 73.81% | 16.10% | 16.52% | 13.84% |
| 2016-12-31 | 72.76% | 16.79% | 19.81% | 9.39% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $557.00M | - |
| 2024-12-31 | $619.00M | - |
| 2023-12-31 | $302.00M | - |
| 2022-12-31 | $350.00M | - |
| 2021-12-31 | $1.28B | - |
| 2020-12-31 | $1.75B | - |
| 2019-12-31 | $257.00M | - |
| 2018-12-31 | $333.00M | $1.30B |
| 2017-12-31 | $155.00M | $1.42B |
| 2016-12-31 | $38.00M | $1.56B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $852.00M | $43.00M |
| 2024-12-31 | $606.00M | $40.00M |
| 2023-12-31 | $181.00M | $39.00M |
| 2022-12-31 | $110.00M | $40.00M |
| 2021-12-31 | $469.00M | $41.00M |
| 2020-12-31 | $492.00M | $26.00M |
| 2019-12-31 | $760.00M | $32.00M |
| 2018-12-31 | $584.00M | $35.00M |
| 2017-12-31 | $714.00M | $31.00M |
| 2016-12-31 | $457.00M | $27.00M |
Dividend history
- Most recent payment
- 2026-03-27
- Paid in the last twelve months
- $0.78
| Payment date | Dividend per share |
|---|
| 2026-03-27 | $0.48 |
| 2025-10-03 | $0.30 |
| 2025-03-28 | $0.46 |
| 2024-10-04 | $0.29 |
| 2024-04-01 | $0.46 |
| 2023-10-05 | $0.29 |
| 2023-03-30 | $0.46 |
| 2022-09-29 | $0.29 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2023-08-03 | - | - |
| 2023-04-01 | - | - |
| 2023-02-28 | - | - |
| 2022-09-30 | - | - |
| 2022-07-02 | - | - |
| 2022-04-02 | - | - |
| 2022-02-24 | - | - |
| 2021-09-30 | - | - |
Filings and sources
- Company website
- smith-nephew.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades